Trial Information
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma
Inclusion Criteria:
- Age ≥ 18 years
- signed informed Consent
- Medical Examination
- Patients with metastatic colorectal cancer
- Patients with a glioblastoma
- patient to receive treatment with bevacizumab not yet started
- MRI for patients with glioblastoma or scanner TAP for patients carrying a metastatic
colon cancer performed within 3 weeks before inclusion.
Exclusion Criteria:
- Bevacizumab already initiated or history of antiangiogenic treatment
- Inability legal (persons deprived of liberty or under guardianship)
- Pregnant or lactating women
- Can not sign consent or unable to undergo medical follow up for geographical, social
or psychological reasons
- Patients not covered by Medicare including CMU
- Estimated life of over 3 months
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
change in the density of capillaries
Outcome Description:
The change in the density of capillaries visualized by periungual capillaroscopy will be quantify after 15 days of treatment with bevacizumab, in patients with metastatic colon cancer or a brain tumor.
Outcome Time Frame:
baseline and after 15 days of bevacizumab treatment
Safety Issue:
No
Principal Investigator
François Ghiringhelli, Professor
Investigator Role:
Principal Investigator
Investigator Affiliation:
Centre Georges Francois Leclerc
Authority:
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study ID:
001-FANI-2012
NCT ID:
NCT01810744
Start Date:
April 2014
Completion Date:
Related Keywords:
- Metastatic Colorectal Cancer
- Glioblastoma
- Bevacizumab
- Capillaroscopy
- Colonic Neoplasms
- Colorectal Neoplasms
- Glioblastoma